RxDoctor Payments Data

Lara Mote

Family · Muncie, INNPI 1407572548

Payments from drug & device makers

$3,410in general payments, 2019–2025

Across 185 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$590
  • Amgen$505
  • Mallinckrodt Hospital Products Inc.$482
  • Pfizer$431
  • AbbVie$277
  • UCB, Inc.$275
  • plus $849 from 10 others

What the payments were for

  • Food & beverage$3,08791%
  • Education$3239%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,410 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$569,636
Medicare patients
267
Services billed
71,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab118$808,544
Enbrel SureclickEtanercept61$476,784
Orencia ClickjectAbatacept53$300,707
Cosentyx Sensoready PenSecukinumab28$241,685
RinvoqUpadacitinib33$207,699
Cimzia (2 Pack)Certolizumab Pegol35$203,430
Cosentyx Unoready PenSecukinumab21$148,525
Humira(Cf)Adalimumab14$92,790
OrenciaAbatacept15$87,650
Actemra ActpenTocilizumab18$72,829
BenlystaBelimumab13$65,399
OtezlaApremilast11$53,969
Hydroxychloroquine Sulfate593$13,580
Leflunomide177$9,886
MethotrexateMethotrexate Sodium396$7,354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$277$300,48947 claims
UCB, Inc.Cimzia (2 Pack)$275$203,43035 claims
E.r. Squibb & Sons, L.L.C.Orencia$89$87,65015 claims
GSKBenlysta$218$65,39913 claims
AmgenOtezla$505$53,96911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.

Other family in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →